CytoDyn Inc. (OTCQB: CYDY), a biotechnology company developing innovative treatments for multiple therapeutic indications, this morning announced that Richard G. Pestell, M.D., Ph.D., president of the Pennsylvania Cancer and Regenerative Medicine Research Center, distinguished professor at the Baruch S. Blumberg Institute and interim chief medical officer of CytoDyn, will deliver the keynote plenary speech at the 11th Annual Conference on Stem Cell and Regenerative Medicine in Helsinki, Finland. Pestell’s presentation, titled ‘Cancer stem cells, genetic drivers and therapeutic targeting via CCR5’, is scheduled to take place on Monday, October 15, from 10-11 am EEST. Pestell will present recent scientific evidence demonstrating the effectiveness of PRO 140 (leronlimab), which is shown to bind to CCR5 in human breast cancer, block CCR5 signaling induced by cytokines and block human breast cancer cell invasion.
To view the full press release, visit http://ibn.fm/V477e
CytoDyn is a biotechnology company developing innovative treatments for multiple therapeutic indications based on PRO 140 (leronlimab), a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 plays a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor is also implicated in tumor metastasis and in immune-mediated illnesses such as graft-vs-host disease (GvHD) and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with PRO 140 in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients. The Company plans to seek FDA approval for PRO 140 in combination therapy and plans to complete the filing of a Biological License Application (BLA) in the first quarter of 2019 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with PRO 140 as a once-weekly monotherapy for HIV-infected patients, and plans to initiate a registration-directed study of PRO 140 monotherapy indication, which if successful, could support a label extension. Clinical results to date from multiple trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, results from a Phase 2b clinical trial demonstrated that PRO 140 monotherapy can prevent viral escape in HIV-infected patients, with some patients on PRO 140 monotherapy remaining virally suppressed for more than four years. CytoDyn is also conducting a Phase 2 trial to evaluate PRO 140 for the prevention of GvHD and expects to initiate clinical trials with PRO 140 in metastatic triple-negative breast cancer in 2018. For more information, visit the company’s website at www.CytoDyn.com
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks has received compensation from CytoDyn Inc. for providing certain investor relations, marketing and social media services, including the preparation of this report, and expects to receive additional compensation for such services in the future. This compensation includes a monthly program fee.